NCT02358005Unknown4 期
Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity
适应症
试验速览
- 阶段
- 4 期
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Range of Motion (ROM) of elbow flexor
研究概览
简要总结
Recently, It is known that the efficacy of botulinum toxin type A (BTX-A) with extracorporeal shock wave therapy (ESWT) is greater than that of BTX-A with electrical stimulation in the management of post-stroke spasticity of the upper limb. However, it was not determined which dose of ESWT is optimal as a adjuvant therapy after BTX-A injection on the upper limb in patients with stroke. Therefore, the aim of this study is to evaluate the optimal dose of ESWT after botulinum toxin type A injection for post-stroke spasticity
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Age ≥20 years
- •inpatients
- •Elbow flexor spasticity in patients, confirmed to be mainly due to biceps brachii
- •Modified Ashworth scale (MAS) ≥2,
- •At least a 3-month period from stroke,
- •Written informed consent has been obtained
排除标准
- •Fixed contractures and/or deformities at the elbow,
- •Previous fractures of the paretic upper limb,
- •Peripheral nervous system disorders/myopathies,
- •Previous BTX-A treatment and/or ESWT,
- •Structural alterations in the soft tissue (e.g., fibrosis),
- •Known allergy or sensitivity to the study medication or its components
- •Presence of an unstable medical condition or uncontrolled systemic disease
- •Any medical condition that may put the patient at increased risk with exposure to botulinum toxin therapy. (ex. Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interface with neuromuscular function.
- •Bleeding tendency and/or anticoagulation therapy
- •Presence of infection or skin disorder at injection sites
- •Females were are pregnant, nursing, or are planning a pregnancy during the study
- •Females of child-bearing potential (including pre-menstrual woman), not using a reliable means of contraception
- •Participant who should be withdrawn from the study in the opinion of the investigator for any reason
结局指标
主要结局
Range of Motion (ROM) of elbow flexor
时间窗: 5 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke SpasticityHemiplegia, SpasticMuscle SpasticityStrokeNCT05889026Korea University Guro Hospital16
已完成
不适用
Efficacy of Extracorporeal Shock Wave Therapy on SpasticitySpasticity, MuscleStrokeNCT06225024Kayseri City Hospital40
已完成
不适用
Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for SpasticityPost-Stroke Upper Limb SpasticityNCT03131791Mackay Memorial Hospital42
已完成
不适用
Comparative Study Between Botulinum Toxin-A Injection and Shock Waves on Hypertrophic Scars in Hand-burned ChildrenHand-burned ChildrenNCT06174155Cairo University60
终止
2 期
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive BladderOveractive BladderNCT00578097Ipsen81